FDA clears DiA's cardiac ultrasound AI

2020 03 04 21 21 6197 Artificial Intelligence Ai Hand 400 20200304215813

Echocardiography image analysis software developer DiA Imaging Analysis has received clearance from the U.S. Food and Drug Administration (FDA) for its LVivo Seamless cardiac ultrasound artificial intelligence (AI) software.

LVivo chooses the best cardiac ultrasound views from standard echocardiogram exams and works with the company's other LVivo offerings such as LVivo EF for automated calculation of ejection fraction, it said.

DiA plans to highlight LVivo at the upcoming virtual RSNA meeting.

Page 1 of 573
Next Page